EP1495143A1 - Detection de mycobacteries dans des materiaux cliniques - Google Patents
Detection de mycobacteries dans des materiaux cliniquesInfo
- Publication number
- EP1495143A1 EP1495143A1 EP03729922A EP03729922A EP1495143A1 EP 1495143 A1 EP1495143 A1 EP 1495143A1 EP 03729922 A EP03729922 A EP 03729922A EP 03729922 A EP03729922 A EP 03729922A EP 1495143 A1 EP1495143 A1 EP 1495143A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- seq
- detection
- pair
- mycobacteria
- rrna
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000012568 clinical material Substances 0.000 title claims abstract description 22
- 238000001514 detection method Methods 0.000 title claims description 94
- 108020004465 16S ribosomal RNA Proteins 0.000 claims abstract description 90
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 60
- 241000186367 Mycobacterium avium Species 0.000 claims abstract description 49
- 241001302239 Mycobacterium tuberculosis complex Species 0.000 claims abstract description 47
- 239000012634 fragment Substances 0.000 claims description 103
- 239000000523 sample Substances 0.000 claims description 99
- 238000009396 hybridization Methods 0.000 claims description 90
- 241000894007 species Species 0.000 claims description 62
- 125000003729 nucleotide group Chemical group 0.000 claims description 60
- 239000002773 nucleotide Substances 0.000 claims description 57
- 238000000034 method Methods 0.000 claims description 56
- 108020004414 DNA Proteins 0.000 claims description 47
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 46
- 239000013612 plasmid Substances 0.000 claims description 46
- 201000008827 tuberculosis Diseases 0.000 claims description 34
- 238000011895 specific detection Methods 0.000 claims description 32
- 238000011880 melting curve analysis Methods 0.000 claims description 27
- 238000003752 polymerase chain reaction Methods 0.000 claims description 26
- 230000000295 complement effect Effects 0.000 claims description 25
- 238000002866 fluorescence resonance energy transfer Methods 0.000 claims description 20
- 208000027531 mycobacterial infectious disease Diseases 0.000 claims description 18
- 206010062207 Mycobacterial infection Diseases 0.000 claims description 17
- 230000000813 microbial effect Effects 0.000 claims description 17
- 150000007523 nucleic acids Chemical class 0.000 claims description 12
- 238000003753 real-time PCR Methods 0.000 claims description 11
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 10
- 108020004707 nucleic acids Proteins 0.000 claims description 8
- 102000039446 nucleic acids Human genes 0.000 claims description 8
- 108091034117 Oligonucleotide Proteins 0.000 claims description 7
- 238000009007 Diagnostic Kit Methods 0.000 claims description 6
- 238000001574 biopsy Methods 0.000 claims description 6
- 206010036790 Productive cough Diseases 0.000 claims description 5
- 210000003802 sputum Anatomy 0.000 claims description 5
- 208000024794 sputum Diseases 0.000 claims description 5
- 210000004369 blood Anatomy 0.000 claims description 4
- 239000008280 blood Substances 0.000 claims description 4
- 210000001185 bone marrow Anatomy 0.000 claims description 4
- 210000004051 gastric juice Anatomy 0.000 claims description 4
- 238000005259 measurement Methods 0.000 claims description 4
- 210000002700 urine Anatomy 0.000 claims description 4
- 210000001175 cerebrospinal fluid Anatomy 0.000 claims description 3
- 238000012217 deletion Methods 0.000 claims description 3
- 230000037430 deletion Effects 0.000 claims description 3
- 238000001917 fluorescence detection Methods 0.000 claims description 2
- 230000008569 process Effects 0.000 claims description 2
- 238000000605 extraction Methods 0.000 claims 1
- 230000003321 amplification Effects 0.000 abstract description 56
- 238000003199 nucleic acid amplification method Methods 0.000 abstract description 56
- 108020005187 Oligonucleotide Probes Proteins 0.000 abstract description 4
- 239000002751 oligonucleotide probe Substances 0.000 abstract description 4
- 238000010170 biological method Methods 0.000 abstract description 2
- 238000002844 melting Methods 0.000 description 42
- 230000008018 melting Effects 0.000 description 42
- 238000006243 chemical reaction Methods 0.000 description 13
- 230000000692 anti-sense effect Effects 0.000 description 9
- 238000013459 approach Methods 0.000 description 9
- 239000000975 dye Substances 0.000 description 9
- 208000015181 infectious disease Diseases 0.000 description 9
- 244000052769 pathogen Species 0.000 description 9
- 230000035945 sensitivity Effects 0.000 description 9
- 241000186359 Mycobacterium Species 0.000 description 8
- 241000186366 Mycobacterium bovis Species 0.000 description 8
- 244000005700 microbiome Species 0.000 description 8
- 238000010790 dilution Methods 0.000 description 7
- 239000012895 dilution Substances 0.000 description 7
- 230000002441 reversible effect Effects 0.000 description 7
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 6
- 230000005764 inhibitory process Effects 0.000 description 6
- 230000035772 mutation Effects 0.000 description 6
- 230000009467 reduction Effects 0.000 description 6
- 241000187478 Mycobacterium chelonae Species 0.000 description 5
- 241000187479 Mycobacterium tuberculosis Species 0.000 description 5
- 206010044756 Tuberculous infections Diseases 0.000 description 5
- 230000001580 bacterial effect Effects 0.000 description 5
- 238000004925 denaturation Methods 0.000 description 5
- 230000036425 denaturation Effects 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical class [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 5
- 108091093088 Amplicon Proteins 0.000 description 4
- 238000003745 diagnosis Methods 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 238000006116 polymerization reaction Methods 0.000 description 4
- 239000011541 reaction mixture Substances 0.000 description 4
- 101150072531 10 gene Proteins 0.000 description 3
- 241000186216 Corynebacterium Species 0.000 description 3
- 201000003883 Cystic fibrosis Diseases 0.000 description 3
- 241001509442 Mycobacterium agri Species 0.000 description 3
- 241000187472 Mycobacterium chitae Species 0.000 description 3
- 241000187494 Mycobacterium xenopi Species 0.000 description 3
- 238000012408 PCR amplification Methods 0.000 description 3
- 239000013611 chromosomal DNA Substances 0.000 description 3
- 238000013399 early diagnosis Methods 0.000 description 3
- 238000007834 ligase chain reaction Methods 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 210000001165 lymph node Anatomy 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 210000003491 skin Anatomy 0.000 description 3
- 208000035473 Communicable disease Diseases 0.000 description 2
- 238000007399 DNA isolation Methods 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 241001508003 Mycobacterium abscessus Species 0.000 description 2
- 241000187482 Mycobacterium avium subsp. paratuberculosis Species 0.000 description 2
- 241001467552 Mycobacterium bovis BCG Species 0.000 description 2
- 241000186365 Mycobacterium fortuitum Species 0.000 description 2
- 241000186363 Mycobacterium kansasii Species 0.000 description 2
- 241000187492 Mycobacterium marinum Species 0.000 description 2
- 241000187476 Mycobacterium triviale Species 0.000 description 2
- ZYFVNVRFVHJEIU-UHFFFAOYSA-N PicoGreen Chemical compound CN(C)CCCN(CCCN(C)C)C1=CC(=CC2=[N+](C3=CC=CC=C3S2)C)C2=CC=CC=C2N1C1=CC=CC=C1 ZYFVNVRFVHJEIU-UHFFFAOYSA-N 0.000 description 2
- 208000009788 Urogenital Tuberculosis Diseases 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 238000000137 annealing Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 238000003759 clinical diagnosis Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000007850 fluorescent dye Substances 0.000 description 2
- 239000003068 molecular probe Substances 0.000 description 2
- 108700022487 rRNA Genes Proteins 0.000 description 2
- 108091008146 restriction endonucleases Proteins 0.000 description 2
- 230000001960 triggered effect Effects 0.000 description 2
- 101150096316 5 gene Proteins 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 108020000946 Bacterial DNA Proteins 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 206010056377 Bone tuberculosis Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 101100268670 Caenorhabditis elegans acc-3 gene Proteins 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 241001522296 Erithacus rubecula Species 0.000 description 1
- 201000009906 Meningitis Diseases 0.000 description 1
- 241000186364 Mycobacterium intracellulare Species 0.000 description 1
- 241000337007 Oceania Species 0.000 description 1
- 208000009360 Osteoarticular Tuberculosis Diseases 0.000 description 1
- 108010002747 Pfu DNA polymerase Proteins 0.000 description 1
- 108010006785 Taq Polymerase Proteins 0.000 description 1
- 101710136739 Teichoic acid poly(glycerol phosphate) polymerase Proteins 0.000 description 1
- KGTSLTYUUFWZNW-PPJQWWMSSA-N [(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate pyridine-4-carbohydrazide Chemical compound NNC(=O)c1ccncc1.CO[C@H]1\C=C\O[C@@]2(C)Oc3c(C2=O)c2c(O)c(\C=N\N4CCN(C)CC4)c(NC(=O)\C(C)=C/C=C/[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)c(O)c2c(O)c3C KGTSLTYUUFWZNW-PPJQWWMSSA-N 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000014670 detection of bacterium Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 239000012470 diluted sample Substances 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000009585 enzyme analysis Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002189 fluorescence spectrum Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 229960003350 isoniazid Drugs 0.000 description 1
- QRXWMOHMRWLFEY-UHFFFAOYSA-N isoniazide Chemical compound NNC(=O)C1=CC=NC=C1 QRXWMOHMRWLFEY-UHFFFAOYSA-N 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 238000009593 lumbar puncture Methods 0.000 description 1
- 238000007403 mPCR Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 201000009671 multidrug-resistant tuberculosis Diseases 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 230000005257 nucleotidylation Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 239000013610 patient sample Substances 0.000 description 1
- 206010034674 peritonitis Diseases 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 101150114864 plcA gene Proteins 0.000 description 1
- 208000008423 pleurisy Diseases 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 239000011535 reaction buffer Substances 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- JQXXHWHPUNPDRT-WLSIYKJHSA-N rifampicin Chemical compound O([C@](C1=O)(C)O/C=C/[C@@H]([C@H]([C@@H](OC(C)=O)[C@H](C)[C@H](O)[C@H](C)[C@@H](O)[C@@H](C)\C=C\C=C(C)/C(=O)NC=2C(O)=C3C([O-])=C4C)C)OC)C4=C1C3=C(O)C=2\C=N\N1CC[NH+](C)CC1 JQXXHWHPUNPDRT-WLSIYKJHSA-N 0.000 description 1
- 229960001225 rifampicin Drugs 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 235000011178 triphosphate Nutrition 0.000 description 1
- 239000001226 triphosphate Substances 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6888—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
- C12Q1/689—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/166—Oligonucleotides used as internal standards, controls or normalisation probes
Definitions
- the present invention relates to a method for the specific detection of mycobacteria and for differentiating the Mycobacterium tuberculosis complex and Mycobacterium avium from other mycobacteria in clinical material.
- Tuberculosis is a worldwide infectious disease that is chronic and costs more lives each year than any other bacterial infection.
- Tuberculosis is particularly localized in the lungs, less often in the cervical lymph nodes, intestine or skin.
- the very different clinical courses of tuberculosis therefore make an exact description of the disease state and a quick diagnosis necessary, especially at early stages of the disease.
- Mycobacteri um tuberculosis and very rarely Mycobacterium bovis are generally summarized under the term "Mycobacterium tuberculosis complex”.
- Non-tuberculous mycobacteria lead to an additional worsening in patients suffering from, for example, cystic fibrosis the clinical picture in the area of the lungs (1, 2, 16).
- the non-tuberculous mycobacteria observed in clinical practice include: Mycobacterium avium, Mycobacterium intracellulare, Mycobacterium kansasii, Mycobacterium marinum, Mycobacterium fortui tum, Mycobacterium chelonae and Mycobacterium abscessus (4).
- the diagnosis of mycobacteria in clinical material should ideally allow specific detection of tuberculous and non-tuberculous mycobacteria.
- PCR polymerase chain reaction
- Genus-specific methods are used to differentiate a mycobacterial infection from other infections.
- Known genus-specific methods target the 16S rRNA gene or the gene of the 65 kDa “heat shock” protein.
- a subsequent specific identification of some types of mycobacteria is carried out using conserved hybridization probes (5, 12).
- the amplified genes are sequenced ( 6) or an analysis using restriction enzymes is carried out (15).
- the specific DNA regions that are used for the species-specific detection of the M. tuberculosis complex by means of PCR include, for example, IS 6110, the genes of the 38 kDa protein, the genes of the MBP 64 protein and the regions mtp40 or pMTb4.
- diagnostic kits which are mostly only suitable for diagnosing the M. tuberculosis complex.
- kits are offered, for example, by Roche-Amplicor TM, Geneprobe TM or Abbot TM.
- the molecular biological methods that are carried out for this purpose include, on the one hand, the duplication of the nucleic acid to be detected (target amplification), for example by means of PCR, by transcription-based isothermal DNA synthesis (TMA), by the ligase chain reaction (LCR) or by the isothermal strand displacement amplification (SDA), on the other hand the duplication of the signaling component (signal amplification), such as by the isothermal Qß replication.
- target amplification for example by means of PCR
- TMA transcription-based isothermal DNA synthesis
- LCR ligase chain reaction
- SDA isothermal strand displacement amplification
- the l ⁇ S rRNA gene is already used for the detection and identification of various human-pathogenic mycobacteria by means of PCR (7).
- an algorithm for the specific duplication of a 1000 bp fragment of the mycobacterial 16S rRNA by means of an unspecific primer and a genus-specific primer for mycobacteria is proposed.
- genus-specific oligonucleotide probes are used which hybridize with the spaceted fragment.
- species-specific hybridization probes are used, whereby the mycobacterial species M. tuberculosis complex and M. avium can be differentiated from other types of bacteria using the same amplified fragment (5).
- DNA extracted from clinical samples contains contaminants that often lead to enzyme-based amplification, especially PCR, being inhibited.
- detection methods known to date there is a great risk that a negative result will be obtained even though the patient actually has a mycobacterial infection.
- existing tuberculosis is overlooked. Therefore, there has long been a need to develop a control system, the so-called "false negative" finding de excludes in the detection procedure (inhibition control).
- fluorimetric measurements especially when used as part of the real-time PCR method, represent a fast and sensitive method for the detection of amplified gene fragments.
- real-time fluorimetry was used to detect M. tuberculosis in expectorates using the TaqMan TM system.
- the LightCycler TM system from Röche Molecular Biochemicals which is an embodiment of real-time PCR, has now also been used to detect M. bovis in Rinderstuhl and to detect mutations in rifampin or isoniazid resistance in M. tuberculosis (11, 13). In these two studies, the multiplied fragments were typically 200 base pairs in length. Due to the high throughput of a LightCycler TM system, it has been assumed up to now that multiplication of larger DNA fragments of mycobacteria is difficult or impossible due to the high CG nucleotide content of approx. 65% up to 75% occurring in mycobacteria.
- genus-specific region II is from the prior art II ", known on the 16S rRNA gene of mycobacteria, whereby by means of a specific hybridization probe pair and a melting curve analysis, a large number of mycobacterial species can be distinguished from other bacterial species and other microorganisms due to a higher melting point of the probe pair (6)
- certain types of mycobacteria such as M. triviale, M. agri, M. Xenopi or M. chitae also have a low melting point, so that, according to the prior art, the mycobacteria are clearly differentiated from non-mycobacteria, especially in a single procedural step is not possible at all.
- the technical problem of the present invention is to provide an improved method, in particular a particularly fast and at the same time more specific detection of mycobacterial infections in clinical material of various origins and the identification of the species M. tuberculosis complex and / or M. avium in enables a common verification procedure.
- the present invention solves the technical problem by providing a method for joint, specific detection of a mycobacterial rieninfediction and the Mycobacterium tuberculosis complex and / or Mycobacterium avium compared to other types of mycobacteria in clinical material, wherein (a) microbial DNA is extracted from the clinical material and then
- At least one fragment of the 16S rRNA gene from the microbial DNA is amplified with a primer pair comprising the nucleotide sequences SEQ ID NO: 1 / SEQ ID NO: 5 or with two primer pairs, the one primer pair containing the nucleotide sequences SEQ ID NO: 2 / SEQ ID NO: 3 and the other pair of primers is used immediately before or after or simultaneously and the nucleotide sequences include SEQ ID NO: 4 / SEQ ID NO: 5, is amplified and then
- the at least one amplified 16S rRNA gene fragment is detected by means of at least one pair of labeled hybridization probes which hybridize with hypervariable species-specific regions of the 16S rRNA fragment of mycobacteria, the pair of labeled hybridization probes for detection of the M. tuberculosis complex includes the nucleotide sequences SEQ ID NO: 6 / SEQ ID NO: 7 or the pair of complementary sequences thereof, and the pair of labeled hybridization probes for the detection of M.
- avium contain the nucleotide sequences of SEQ ID NO: 8 / SEQ ID NO: 9 or the pair of the complementary sequences thereof, and then, simultaneously or immediately before (d) the at least one amplified 16S rRNA gene fragment is detected by means of a pair of labeled hybridization probes which hybridizes with the genus-specific region III of the 16S rRNA fragment, the pair having the nucleotide sequences SEQ ID NO: 10 / SEQ ID NO: 11 or the pair of complementary sequences thereof, and wherein
- steps (e) the specific detection of the mycobacteria genus, and the detection of the M. tuberculosis complex and / or of M. avium in steps (c) and (d) is carried out by means of melting curve analysis.
- the invention therefore advantageously provides that the detection of mycobacteria as a genus together with the species-specific detection of M. tuberculosis complex is made possible in a uniform common procedure.
- the invention also enables a common uniform specific detection of the genus Mycobacterium together with the species-specific detection of M. avium.
- the invention also enables the joint specific detection of bacteria of the genus ycojacterium together with the species-specific detection of M. tuberculosis complex and M. avium.
- a major advantage of the method according to the invention is that in the combined detection method used to diagnose mycobacterial infections, both an existing mycobacterial infection compared to other microbial infections and an existing tuberculosis compared to non-tuberculous infections are clear and reliable can be recognized. This proof was not possible in such an advantageous manner according to the prior art.
- the unequivocal detection of a mycobacterial infection compared to other microbial infections takes place by analyzing the melting temperatures of the hybridization of the genus-specific hybridization probe pair, which contains the nucleotide sequences SEQ ID NO: 10 / SEQ ID NO: 11 or the pair of the complementary sequences thereof, with the Genus-specific region III of the 16S rRNA gene took place.
- mycobacterial strains are characterized by melting temperatures of at least 55 ° C., in particular 55 ° C. and 61.5 ° C.
- the mycobacterial strain M. chelonae can be clearly identified compared to all other mycobacterial strains, which in particular have a melting temperature of 61.5 ° C, and a mycobacterial infection by M. chelonae can be detected ,
- the method according to the invention permits, in addition to the clear and reliable detection of a tuberculous infection, the clear and reliable detection of a non-tuberculous infection triggered by M. avium.
- strains of the M. tuberculosis complex are distinguished by melting temperatures of at least 55 ° C., in particular 64 ° C.
- the unequivocal detection of a tuberculous infection by M. avium takes place by analyzing the melting temperatures of the hybridization of the type-specific hybridization probe pair for M. avium, the nucleotide sequences SEQ ID NO: 8 / SEQ ID NO: 9 or the pair of complementary sequences of which includes the species-specific region of the 16S rRNA gene.
- M. avium is characterized by melting temperatures of at least 55 ° C., in particular 6.1 ° C.
- the above-mentioned method is preferably carried out with an internal standard according to the invention in the form of artificial plasmids, control plasmids, for identifying so-called “false-negative” findings.
- a first part of the extracted microbial DNA complies with the aforementioned Method with steps (a) to (e) is subjected and a second part of the extracted microbial DNA in a parallel to the aforementioned method approach (a ') is mixed with at least one artificial plasmid, preferably subcloned in pGEM-T, which serves as an internal standard, the artificial plasmid comprising a genus-specific region III of the 16S rRNA with a modified nucleotide sequence, and then
- the multiplied 16S rRNA fragments are detected by means of a pair of labeled hybridization probes which hybridize with the modified genus-specific region III, the pair of labeled hybridization probes comprising the nucleotide sequences SEQ ID NO: 10 / SEQ ID NO: 11 and where (d ') during the detection the specific detection of the 16S rRNA fragments of mycobacteria and the modified 16S rRNA fragments of the internal standard is carried out by means of melting curve analysis.
- steps (a), (b), (c), (d) and (e) of the aforementioned method are carried out, the at least one artificial plasmid in step (a) using the total extracted microbial DNA is mixed and, after application according to step (b), the detection and melting curve analysis to detect the multiplied 16S rRNA fragments of mycobacteria and the modified 16S rRNA fragments of the internal standard, in particular simultaneously, according to steps (c ') and (d') is carried out.
- control plasmid in the detection method according to the invention, it is advantageously possible to check the success of the amplification reaction already during the detection reaction of mycobacteria in order to obtain a reliable and clear result particularly quickly.
- so-called “false-negative” findings in the case of inhibition of amplification are practically excluded by using the plasmid according to the invention as an internal standard.
- the specificity and selectivity of the method according to the invention are thus significantly increased compared to the prior art.
- the formulations “comprising a primer pair or comprising the nucleotide sequences”, “comprising a pair of hybridization probes or comprising the nucleotide sequences” or the like mean that the respective nucleotide sequences or the pair of nucleotide sequences each have the nucleotide sequences referred to / has, that is to say that these nucleotide sequences or the pair thereof consist / consist of the specifically named nucleotide sequence alone or optionally comprise / comprise further sequences.
- Mycojacteriu-n tuberculosis complex refers to the tuberculous mycobacterial species Mycobacterium tuberculosis, in particular the strain H37Rv, and Mycobacterium bovis, in particular the R99 strain, these strains causing the disease tuberculosis, and the BCG Pasteur strain of Mycobacterium bovis.
- the term "tubercular” describes a property which relates to Mycobacterium tuberculosis, in particular the strain H37Rv, and Mycobacterium bovis, in particular the strain R99, in the narrower sense and to the strain BCG Pasteur of Mycobacterium bovis in refers to the wider sense and causes the clinical picture of tuberculosis.
- Mycobacterium avium is understood to mean the non-tuberculous Mycobacterium species Mycobacterium avium, in particular the strain ATCC35712, and their subspecies Mycobacterium paratuberculosis, in particular the strain Pat.6783.
- non-tuberculous is understood to mean a property which is related to a disease other than tuberculosis and is in particular a mycobacteriosis.
- clinical material is understood to mean clinical samples such as sputum, bronchial lavage, gastric juice, urine, stool, cerebrospinal fluid, bone marrow, blood or biopsies, in particular punctate biopsies, for example from cervical lymph nodes.
- modified nucleotide sequence is understood to mean a nucleic acid sequence which is derived from its original sequence, ie the wild-type sequence, by exchange, inversion, deletion or addition of at least one nucleotide, including an unusual or synthetic nucleotide , in at least one nucleotide, preferably in two nucleotides.
- modified is understood to mean a property which relates to a "modified nucleotide sequence”.
- the amplification of the gene fragments of the 16S rRNA gene is carried out by means of the polymerase chain reaction (PCR).
- the amplification is preferably carried out by real-time PCR (rapid cycle PCR).
- real-time PCR rapid cycle PCR
- the amplification is particularly preferably carried out in a LightCycler TM system from Röche Molecular Biochemicals, which is an embodiment of the real-time PCR.
- the PCR starting mixture in addition to the polymerase, the nucleotides, the buffer solutions and the primers, also hybridization probes which specifically bind to the desired PCR amplification products are added.
- two sequence-specific oligonucleotide probes are used, which are labeled with different dyes.
- the sequences of the Labeled hybridization probe pairs according to the invention are selected such that they hybridize to the target sequences of the amplified DNA fragment in such a way that in particular the 3 'end of one probe is close to the 5' end of the other probe, as a result of which the two dyes be brought into close proximity to one another, in particular the distance between the two probes is between 1 and 5 nucleotides.
- FRET fluorescence resonance energy transfer
- the FRET system quantitative measurements of the amount of amplified DNA fragments are provided by the FRET system.
- the hybridization probes selected according to the invention can bind quantitatively, ie stoichiometrically, to the amplified fragments.
- the quantitative hybridization is particularly dependent on the temperature and the degree of homology of the oligonucleotide probes used with the detected sequence on the amplified fragment.
- the aforementioned fluorimetric detection of specific DNA sequences in the amplified fragments is carried out after amplification of the fragments by means of conventional PCR.
- the fluorimetric de- tection carried out in a real-time PCR during the amplification reactions for example the increase in DNA produced can be tracked as an increase in the fluorescence signal.
- the specific detection of species-specific and / or genus-specific regions in the amplified DNA fragment takes place after the end of the amplification reaction, the hybridization probe pair, preferably a FRET pair, being hybridized the regions to be detected, the temperature is changed in the course of a melting curve analysis, preferably continuously increased, and at the same time the fluorescence emitted as a function of the temperature is measured. In this way, a melting temperature is determined at which the hybridization probes, in particular the FRET pair used, no longer hybridize to the region of the amplified DNA fragment to be detected.
- the essential aspect of a melting curve analysis is that if there are mismatches between the pair of hybridization probes used and the target region on the approved DNA fragment, the measured melting point is reduced.
- the regions of DNA fragments whose sequences differ only slightly, in particular by one or a few point mutations, in the nucleotide sequence are identified with hybridization probes, in particular with a FRET pair.
- the 16S rRNA gene of mycobacteria advantageously has both conserved and highly variable regions which, for example, permit genus-specific amplification of DNA fragments using genus-specific primers.
- the aforementioned methods of fluorescence detection are therefore used in conjunction with the melting curve analysis for the specific detection of the genus-specific region III and the hypervariable species-specific regions of the M. tuberculosis complex and M. avium on the 16S rRNA gene.
- primer pairs are additionally shown schematically, which are used to amplify the selected species-specific or genus-specific regions.
- the primer pair comprising the nucleotide sequences SEQ ID NO: 1 and SEQ ID NO: 5 is used to amplify the gene-specific region III 16S rRNA gene from mycobacteria.
- the primer pair consists of degenerate or mutated sequences or fragments thereof, each of which hybridizes with the nucleotide sequences SEQ ID NO: 1 and SEQ ID NO: 5, from which they are derived, where in each case there is a degree of homology of at least 90%, preferably at least 95%, particularly preferably at least 98%.
- the 1000 bp long fragment amplified with the aforementioned primer pair contains both the conserved genus-specific region III and the highly variable species-specific regions of the M. tuberculosis complex and M. avium.
- the additional or alternative use of two further primer pairs is also provided, a primer pair amplifying a 300 bp fragment in particular of the l ⁇ S rRNA gene from mycobacteria which contains specific regions of the M. tuberculosis complex and M. avium, this primer pair consisting of the nucleotide sequences SEQ ID NO: 2 / SEQ ID NO: 3, and the second primer pair amplifying a 100 bp long fragment of the same gene which amplifies the Contains genus-specific region III, this primer pair comprising the nucleotide sequences SEQ ID NO: 4 / SEQ ID NO: 5.
- the two primer pairs consist of the pairs of degenerate or mutated sequences or fragments thereof, each with the nucleotide sequence pairs SEQ ID NO: 2 / SEQ ID NO: 3 and SEQ ID NO: 4 / SEQ ID NO: hybridize 5, of which they are derived, in each case a degree of homology of at least 90 1%, preferably at least 95%, more preferably consists of at least 98%.
- a pair of labeled hybridization probes is used to detect the aforementioned amplified 16S rRNA fragments of mycobacteria which contain the genus-specific region III and / or the species-specific regions of the M. tuberculosis complex and M. avium of the conserved genus-specific region III, which pair contains the nucleotide sequences SEQ ID NO: 10 / SEQ ID NO: 11 or the complementary sequences thereof.
- the detection of the aforementioned '16S rRNA fragments containing the species-specific regions is carried out with at least one pair of labeled hybridization probes, the labeled hybridization probe pairs preferably being in the form of FRET pairs.
- the type-specific hybridization probe pairs according to the invention are used for the specific detection of the mycobacterial species M. tuberculosis complex and M.
- the rhodamine derivative is LightCycler-Red 640; in further preferred variants of the aforementioned embodiment, the rhodamine derivative is LightCycler-Red 705; in further preferred variants of the aforementioned embodiment, the rhodamine derivative is Cy5.
- the same donor-acceptor dyes are used for labeling the hybridization probe pairs, preferably fluorescein / LightCycler-Red 640, the melting curve analysis using the species-specific probe pair to detect mycobacteria in time or spatially separated from the melting curve analysis using one of the species-specific hybridization probe pairs for the detection of the M. tuberculosis complex or of M. avium, in particular in parallel approaches.
- the melting curve analysis using the species-specific probe pair for the detection of mycobacteria preferably with fluorescein / LightCycler-Red 640 is marked, temporally and spatially together in an approach with melting curve analysis with one of the species-specific hybridization probe pairs, which is preferably labeled with Fluorescein / LightCycler-Red 705, for the detection of the M. tuberculosis complex or of M. avium takes place, preferably in LightCycler TM system the fluorescence of the genus-specific probe pair with one photodetector channel and the fluorescence of a species-specific probe pair with the second photodector channel is registered.
- another object of the present invention are oligonucleotide primer pairs for the duplication of 16S rRNA fragments from extracted bacterial DNA for the specific detection of mycobacteria and for the differentiation of the Mycobacterium tuberculosis complex and Mycobacterium avium from other types of mycobacteria in clinical material, whereby a A pair of primers comprising nucleotide sequences SEQ ID NO: 2 / SEQ ID NO: 3 or a pair of degenerate or mutated nucleotide sequences or fragments thereof.
- degenerate or mutated nucleotide sequences have the property of hybridizing in each case with the sequences SEQ ID NO: 2 / SEQ ID NO: 3, with a degree of homology of at least 90%, preferably at least 95%, particularly preferably at least 98%. , is preferred.
- the invention also relates to a second pair of primers with a primer with the nucleotide sequence SEQ ID NO: 4 or a degenerate or mutated nucleotide sequence or a fragment thereof which hybridizes with the sequence SEQ ID NO: 4, a degree of homology of at least 90%, preferably of at least 95%, particularly preferably at least 98% is preferred.
- another object of the present invention are oligonucleotide hybridization probe pairs for the specific detection of mycobacteria and for differentiating the Mycobacterium tuberculosis complex and Mycobacterium avium from other mycobacterial species in clinical material, selected from the group consisting of the nucleotide sequences SEQ ID NO: 10 / SEQ ID NO: 11 or the pair of complementary sequences thereof, the nucleotide sequences SEQ ID NO: 6 / SEQ ID NO: 7 or the pair of complementary sequences thereof and the nucleotide sequences SEQ ID NO: 8 / SEQ ID NO: 9 or the pair of complementary sequences thereof.
- another object of the present invention is an artificial plasmid, control plasmid, preferably obtained by subcloning the 16S rRNA gene in pGEM-T, which acts as an internal control of the amplification (inhibition control) and the specific detection of 16S -rRNA fragments of mycobacteria and contains a nucleic acid sequence of the modified genus-specific region III of the 16S rRNA gene.
- the control plasmid according to the invention is preferably by nucleotide exchange, nucleotide addition, nucleotide deletion and / or nucleotide inversion of at least one nucleotide, preferably two nucleotides, of the wild-type nucleic acid sequence of the genus-specific region III of the 16S rRNA. Gene derived.
- the artificial plasmid comprises the nucleotide sequence SEQ ID NO: 14 or SEQ ID NO: 15, in each case one nucleotide compared to the wild-type sequence is exchanged. Particularly surprisingly, it was found that the replacement of the one nucleotide resulted in a reduction in the melting temperature of the genus-specific hybridization probes of approximately 1 ° C.
- the artificial plasmid comprises the nucleotide sequence SEQ ID NO: 16 or SEQ ID NO: 17, in each of which two nucleotides are exchanged for the wild-type sequence.
- the replacement of the two nucleotides leads to a reduction in the melting temperature of the genus-specific hybridization probes of approximately 14.5 ° C.
- the present invention furthermore relates to a diagnostic kit for the specific detection of a mycobacterial infection and of M. tuberculosis and M. avium in clinical material according to the methods according to the invention, the at least one polymerase, at least one, preferably all of the aforementioned primer pairs and comprises at least one, preferably all, of the aforementioned hybridization probe pairs.
- the diagnostic kit preferably additionally comprises at least one artificial control plasmid according to the invention as an internal standard.
- SEQ ID NO: 2 "sense" primer ("forward" primer) of the primer pair for the amplification of a 300 bp fragment of the 16S rRNA gene of mycobacteria, containing the species-specific regions of the M. tuberculosis complex and by M. avium,
- SEQ ID NO: 3 "antisense” primer ("reverse” primer) of the primer pair for the amplification of a 300 bp fragment of the 16S rRNA gene from mycobacteria, containing the species-specific regions of the M. tuberculosis complex and by M. avium,
- SEQ ID NO: 4 "sense" primer ("forward” primer) 'of the primer pair for the amplification of a 100 bp fragment of the 16S rRNA gene of mycobacteria, containing the genus-specific region III of the genus Mycobacterium,
- SEQ ID NO: 5 "antisense” primer ("reverse” primer) a) of the primer pair for the amplification of a 1000 bp fragment of the 16S rRNA gene from the mycobacteria, containing the species-specific regions of the M. tuberculosis Complex and of M.
- SEQ ID NO: 7 "sense" hybridization probe, in particular acceptor component, of the probe pair for the detection of the species-specific region of the M. tuberculosis complex
- SEQ ID NO: 8 "antisense" hybridization probe, in particular donor component, of the probe pair for detection of the species-specific region of M. avium,
- SEQ ID NO: 9 “sense” hybridization probe, in particular acceptor component, of the probe pair for detecting the species-specific region of M. avi um, ⁇
- SEQ ID NO: 10 "antisense" hybridization probe, in particular donor component, of the probe pair for the detection of the genus-specific region III of the genus Mycobacterium,
- SEQ ID NO: 11 "sense" hybridization probe, in particular acceptor component, of the probe pair for the detection of the genus-specific region III of the genus Mycobacterium,
- SEQ ID NO: 14 modified "sense" primer ("forward" primer) for the amplification of a complete control plasmid, containing a modified genus-specific region III of the 16S rRNA gene of mycobacteria,
- SEQ ID NO: 15 modified "antisense” primer ("reverse” primer) for the amplification of a complete control plasmid, containing a modified genus-specific region III of the 16S rRNA gene of mycobacteria,
- SEQ ID NO: 17 modified "antisense" primer ("reverse” primer) for the amplification of a further complete control plasmid, containing a further modified genus-specific region III of the 16S rRNA gene of mycobacteria.
- FIG. 1 Schematic representation of the 16S rRNA gene of mycobacteria (length: 1523 bp), the position of the species-specific regions, "species (A)” and “species (B)", and the genus-specific regions “genus I”, “genus II” and “genus III”, and the location and size of the means the
- Primer pairs (1) and (5), (2) and (3) and (4) and (5) amplified fragments.
- Figure 3 Modified 16S rRNA fragment as an internal standard (pJL6): melting curves of the hybridization of the genus-specific hybridization probes with the genus-specific region III and the modified genus-specific region III of the internal standard (pJL6) with a different number of genomes - pien of the genus-specific region III.
- Figure 4 Modified 16S rRNA fragment as an internal standard (pJL6): melting curves of the hybridization of the genus-specific hybridization probes with the genus-specific region III and the modified genus-specific region III of the internal standard (pJL6) in the presence of different amounts of "background" DNA from E. coli.
- Microbial DNA is purified from clinical samples consisting of sputum, bronchial lavage, gastric juice, urine, stool, cerebrospinal fluid, bone marrow, blood or punctate biopsies in a manner known per se, for example using a Qiamp TM MiniKit (company Qiagen, catalog No. 51306) , that is extracted. Chromosomal DNA is quantified using the PicoGreen TM system (Molecular Probes).
- Microbial DNA of different cultures of microorganisms is isolated in particular for evaluating the detection methods according to the invention.
- microbial DNA is isolated from these cultures.
- the microbial DNA is then purified in a manner known per se, for example using a Qiamp TM MiniKit (company Qiagen, catalog no. 51306), that is to say extracted.
- Chromosomal DNA is quantified in a manner known per se, for example using the PicoGreen TM system (Molecular Probes).
- the primer pair a) SEQ ID NO: 1 / SEQ ID NO: 5 is used for the amplification, which amplifies a 1000 bp fragment of the 16S rRNA containing the genus-specific region III and the species-specific regions.
- the two primer pairs b) are used simultaneously in a multiplex PCR batch, in parallel batches or at different times, the primer pair containing SEQ ID NO: 2 / SEQ ID NO: 3 being 300 bp long Fragment of the 16S rRNA containing the species-specific regions, amplified and used for the subsequent detection of the M. tuberculosis complex and / or M. avium, and wherein the primer pair containing SEQ ID NO: 4 / SEQ ID NO: 5 a 100 bp fragment of the 16S rRNA containing the genus-specific region III, amplified and used for the subsequent detection of a mycobacterial infection.
- the pair of probes c) SEQ ID NO: 10 / SEQ ID NO: 11 or a complementary or mutated or degenerate pair thereof is used for the detection of the genus-specific region III. If the M. tuberculosis complex is only to be detected in the method according to the invention in addition to the genus-specific detection, the pair of probes d) SEQ ID NO: 6 / SEQ ID NO: 7 or their equivalents, ie mutated or complementary pairs thereof, are used. On the other hand, if only mycobacteria of the type M.
- the probe pair e) SEQ ID NO: 8 / SEQ ID NO: 9 or their equivalents, ie mutated or complementary pairs thereof, are used. If both the M. tuberculosis complex and M. avium are to be detected together with the genus-specific region III, both probe pairs d) and e) are used in addition to the probe pair c).
- This reaction mixture is brought into the glass capillaries of the LightCycler TM system by pulse centrifugation and the amplification according to the "hot start" principle is carried out after an initial denaturation at 95 ° C. for 10 minutes with the following steps: 1. Denaturation at 95 C for 3 seconds
- Steps 1 to 3 are carried out cyclically a total of 50 times, with the hybridization in step 2 taking place at 68 ° C. for the first 5 cycles and the temperature being reduced to 62 ° C. in steps of 1 ° C. per cycle in the subsequent 6 cycles and is carried out at 62 ° C for the remaining cycles.
- the rate of temperature change in all steps is 20 ° C per second.
- the FRET-labeled hybridization probe pairs used in the reaction mixture are used to detect the amplified fragments, one hybridization probe partner in each case
- SEQ ID NO: 10 SEQ ID NO: 6 or SEQ ID NO: 8
- SEQ ID NO: 11 SEQ ID NO: 7 or SEQ ID NO: 9
- LightCycler TM -Green 640 is associated with LightCycler TM -Green 640 as acceptor component on the 5 'terminal nucleotide.
- the melting curve analysis carried out in the course of the detection begins with the denaturation of the amplified fragments at 95 ° C. for 30 seconds, followed by hybridization with the aforementioned FRET pairs at 38 ° C. for 30 seconds. To determine Following the melting curve of the hybridization, the temperature is then continuously increased from 38 ° C. to 80 ° C. at a rate of 0.2 ° C./sec, the fluorescence emitted by the FRET pairs being continuously recorded. Version 3.5.3 of the LightCycler "Run Profile" program is used to evaluate the fluorescence signal, with the gain of the F2 channel of the photometric detector of the LightCycler TM system being set automatically.
- the entire 16S rRNA gene of mycobacteria (1523 bp) is first included amplified a pair of PCR primers, the “sense” primer consisting of the nucleotide sequence SEQ ID NO: 12 and the “antisense” primer consisting of the nucleotide sequence SEQ ID NO: 13.
- the “sense” primer consisting of the nucleotide sequence SEQ ID NO: 12
- the “antisense” primer consisting of the nucleotide sequence SEQ ID NO: 13.
- the genus-specific region III of the 16S rRNA contained in the artificial plasmid should differ from the wild-type nucleotide sequence of the genus-specific region III by at least one point mutation.
- modified primer pairs are used for the multiplication of the plasmids containing the subcloned fragments, in which one or two nucleotides in the nucleotide sequences were exchanged for the wild-type nucleotide sequences ,
- primer pairs derived from the wild-type sequence of the genus-specific region III, in particular from the region binding the acceptor component of the FRET pair according to the invention, SEQ ID NO: 11, are used for this purpose: a) Exchange of a nucleotide:
- nucleotide sequences according to the invention of the aforementioned modified primer pairs the underlined nucleotide was replaced in each case by the wild-type sequence of the genus-specific region III.
- control plasmids with the modified primer pairs is in each case in a "long range” PCR with a Pfu polymerase, type: "Pfu Turbo Hot Start DNA” (Stratagene) in a manner known per se in a "hot start” PCR procedure carried out with 18 cycles of the following steps:
- Results a) The amplicons obtained are additionally purified using a gel and the point mutations can then be confirmed by sequencing.
- a control plasmid is obtained by using the primers SEQ ID NO: 16 and SEQ ID NO: 17 according to the invention which contains a 16S rRNA fragment modified by exchanging two nucleotides. 50 copies of the control plasmid are mixed as an internal standard with different numbers of gene copies of the 16S rRNA gene from M. tuberculosis and subjected to the detection method according to Example 1. Result :
- This internal standard can therefore also be used if • it can be expected that the number of gene copies to be detected in the clinical material will be an order of magnitude less than the number of plasmid copies used as the internal standard.
- a control plasmid (which contains a 16S rRNA fragment modified by exchanging two nucleotides) is obtained by using the primers SEQ ID NO: 16 and SEQ ID NO: 17 according to the invention. 50 copies of the control plasmid and 10 gene copies of the 16S rRNA gene from M. tuberculosis are mixed with different amounts of "background" DNA from E. coli in the range from 1 pg to 200 ng and then according to the detection method Example 1 subjected. Result :
- the detection method according to the invention in particular using this internal standard, is thus also possible if it can be expected that a large amount of foreign DNA, “background” DNA, is present in the isolated clinical material.
- Example 3 Assessment of the performance of the detection method according to the invention on the LightCycler TM system
- genomic DNA of the bacterial strain Mycobacterium bovis BCG of the M. tuberculosis complex is used as a “template”.
- Example 4 Specific amplification of 16S rRNA fragments from mycobacteria (according to the invention)
- Example 1 In a first approach according to Example 1, a 100 bp fragment of the genus-specific region III (SEQ ID NO: 4 / SEQ ID NO: 5) and a 300 bp fragment of the species-specific regions (SEQ ID NO: 2 / SEQ ID NO: 3) amplified. In a second approach according to Example 1, a 1000 bp long fragment, which contains both the genus-specific region III and the two species-specific regions, is amplified with the corresponding primer pair (SEQ ID NO: 1 / SEQ ID NO: 5).
- the 1000 bp fragment amplified with the primer pair SEQ ID NO: 1 / SEQ ID NO: 5 is used in the detection method according to the invention (Example 1).
- a dilution series of the M. avium genome is prepared and a melting curve analysis of the amplified fragments is carried out with the corresponding hybridization probe pairs.
- a 1000 bp fragment of the 16S rRNA gene is amplified with the genus-specific primer pair SEQ ID NO: 1 / SEQ ID NO: 5.
- a melting curve analysis of the amplified fragments using the hybridization probe pair SEQ ID NO: 10 / SEQ ID NO: 11, specific for the genus-specific region III, is carried out.
- the melting point of amplified 16S rRNA fragments of the genus Corynebacterium is 43 ° C, or no hybridization signal can be detected at all.
- genomic DNA from the microorganisms listed in Table 1 are first used, and each 1000 bp fragment is amplified.
- a melting curve analysis of the amplicons is then carried out using the species-specific hybridization probe pair SEQ ID NO: 6 / SEQ ID NO: 7.
- the melting temperature for the types of the M. tuberculosis complex is a uniform 64 ° C
- the melting temperature for all non-tuberculous pathogens is between 43.5 ° C and 54 ° C, if a hybridization signal can be detected at all (Table 1) ,
- tubercular pathogens can be selectively detected compared to all other non-tubercular pathogens.
- genomic DNA of the microorganisms listed in Table 1 are used first and a 1000 bp long fragment is amplified in each case.
- a melting curve analysis of the amplicons is then carried out using the species-specific hybridization probe pair SEQ ID NO: 8 / SEQ ID NO: 9. Result :
- the melting temperature for M. avium is a uniform 61 ° C
- the melting temperature for all other pathogens is between 43 ° C and 54 ° C, if a hybridization signal can be detected at all (Table 1).
- the non-tuberculous M. avium pathogen can be selectively detected compared to all other pathogens.
- Example 7 Comparative example for the specificity of the genus-specific detection by means of the genus-specific region II ("genus II")
- Example 8 Quantitative determination of the mycobacterial content in clinical samples (according to the invention)
- the degree of fluorescence in this wavelength range is a function of the amount of DNA present and detected in the sample under certain conditions.
- the FRET system enables quantitative measurements of the amount of amplified DNA fragments if the selected hybridization probes bind quantitatively, ie stoichiometrically, to the amplified fragments.
- the standard is measured separately from the samples to be examined, using at least five different concentrations to create a standard curve. If the plasmid pIJ6 is used, a concentration of the standard can be used in each sample examined.
- the distinction between standard and "target DNA" is based on the different melting point.
- the standard serves in particular as a control that the amplification was not inhibited by interference factors (inhibition control).
- the FRET-labeled hybridization probe pairs used in the reaction mixture are used to detect the amplified fragments.
- the amplification reaction proceeds as in Example 1, with the fluorescence being measured after each amplification step.
- the optimal annealing temperature is 62 ° C.
- the melting point analysis is carried out unaffected after completion of the amplification reaction as in Example 1 c). Table 1:
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Analytical Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
La présente invention concerne un procédé de biologie moléculaire permettant de détecter de manière spécifique les mycobactéries et de différencier la mycobactérie du complexe tuberculosis et la mycobactérie avium d'autres mycobactéries dans un matériau clinique à l'aide d'amorces d'amplification et de sondes oligonucléotidiques qui sont spécifiques aux régions spécifiques au genre et à l'espèce du gène 16S-ARNr de mycobactéries.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10215238 | 2002-04-06 | ||
| DE10215238A DE10215238C1 (de) | 2002-04-06 | 2002-04-06 | Nachweis von Mykobakterien in klinischem Material |
| PCT/EP2003/003533 WO2003085129A1 (fr) | 2002-04-06 | 2003-04-04 | Detection de mycobacteries dans des materiaux cliniques |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EP1495143A1 true EP1495143A1 (fr) | 2005-01-12 |
Family
ID=27588608
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP03729922A Withdrawn EP1495143A1 (fr) | 2002-04-06 | 2003-04-04 | Detection de mycobacteries dans des materiaux cliniques |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20060088833A1 (fr) |
| EP (1) | EP1495143A1 (fr) |
| AU (1) | AU2003240448A1 (fr) |
| CA (1) | CA2481517A1 (fr) |
| DE (1) | DE10215238C1 (fr) |
| WO (1) | WO2003085129A1 (fr) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006108205A2 (fr) * | 2005-04-15 | 2006-10-19 | Thomas Schlederer | Procede de detection de fragments d'acide nucleique |
| EP2479273A3 (fr) * | 2006-12-18 | 2012-10-10 | Wako Pure Chemical Industries, Ltd. | Amorce et sonde pour la détection de Mycobacterium avium et procédé pour la détection de Mycobacterium avium les utilisant |
| KR101413659B1 (ko) * | 2007-12-06 | 2014-07-01 | 삼성전자주식회사 | 실시간 핵산 증폭 데이터로부터 시료 중의 표적 핵산의초기 농도를 결정하는 방법 |
| CN102076849A (zh) * | 2008-12-16 | 2011-05-25 | 爱科来株式会社 | 核酸扩增的对照的检测方法及其用途 |
| WO2010111509A1 (fr) * | 2009-03-25 | 2010-09-30 | Life Technologies Corporation | Adn témoin de discrimination positive/d'extraction |
| CN103451313B (zh) * | 2013-09-27 | 2016-03-09 | 中国科学院上海微系统与信息技术研究所 | 一种基因芯片的金沉积检测方法 |
| US10619219B2 (en) * | 2014-02-07 | 2020-04-14 | University Of Iowa Research Foundation | Oligonucleotide-based probes and methods for detection of microbes |
| EP3688181A4 (fr) | 2017-09-29 | 2021-06-16 | University of Iowa Research Foundation | Compositions et procédés numériques de détection de nucléase |
| CN112538539B (zh) * | 2020-11-26 | 2022-09-23 | 中国医学科学院北京协和医院 | 用于鸟分枝杆菌检测的试剂盒及系统 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH05501052A (ja) * | 1989-07-11 | 1993-03-04 | マイクロプローブ・コーポレーション | 核酸ハイブリッド形成アッセイを使用する細菌の定量 |
| DK0528306T3 (da) * | 1991-08-15 | 2000-04-25 | Hoffmann La Roche | Mycobacterium-primerpar |
| CA2135073C (fr) * | 1992-05-06 | 2002-11-19 | Daniel L. Kacian | Procede, composition et trousse d'amplification des sequences d'acides nucleiques |
| US6136529A (en) * | 1993-09-03 | 2000-10-24 | Gen-Probe Incorporated | Nucleic acid probes to Mycobacterium avium complex |
| EP0763134A2 (fr) * | 1994-05-13 | 1997-03-19 | Abbott Laboratories | Materiaux et procedes de detection de microbacteries |
| US6140054A (en) * | 1998-09-30 | 2000-10-31 | University Of Utah Research Foundation | Multiplex genotyping using fluorescent hybridization probes |
| AU2001241934A1 (en) * | 2000-03-03 | 2001-09-17 | Beckman Coulter Inc. | Multiplex hybridization system for identification of pathogenic mycobacterium and method of use |
| KR100433260B1 (ko) * | 2000-09-15 | 2004-05-24 | 주식회사 에스제이하이테크 | 멀티플렉스 pcr 방법 및 이를 이용한 마이코박테리아동정용 키트 및 올리고 뉴클레오티드 |
-
2002
- 2002-04-06 DE DE10215238A patent/DE10215238C1/de not_active Expired - Fee Related
-
2003
- 2003-04-04 CA CA002481517A patent/CA2481517A1/fr not_active Abandoned
- 2003-04-04 AU AU2003240448A patent/AU2003240448A1/en not_active Abandoned
- 2003-04-04 WO PCT/EP2003/003533 patent/WO2003085129A1/fr not_active Ceased
- 2003-04-04 US US10/510,329 patent/US20060088833A1/en not_active Abandoned
- 2003-04-04 EP EP03729922A patent/EP1495143A1/fr not_active Withdrawn
Non-Patent Citations (1)
| Title |
|---|
| See references of WO03085129A1 * |
Also Published As
| Publication number | Publication date |
|---|---|
| US20060088833A1 (en) | 2006-04-27 |
| CA2481517A1 (fr) | 2003-10-16 |
| WO2003085129A1 (fr) | 2003-10-16 |
| DE10215238C1 (de) | 2003-08-14 |
| WO2003085129A8 (fr) | 2003-12-31 |
| AU2003240448A1 (en) | 2003-10-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Luthra et al. | Novel 5′ exonuclease-based real-time PCR assay for the detection of t (14; 18)(q32; q21) in patients with follicular lymphoma | |
| DE60131284T2 (de) | Methode zum nachweis von mikroorganismen | |
| DE69807293T2 (de) | Multiplex-PCR zum Nachweis von Infektionen verursacht durch Mycobacterium Avium Komplex | |
| DE69113261T2 (de) | Hybridizierungssonden von dem abstand zwischen den 16s und 23s rna genen und nachweis von nicht-viralen mikroorganismen. | |
| DE19732086C2 (de) | Verfahren zur quantitativen Bestimmung von Eubakterien | |
| DE60030145T2 (de) | Nachweisverfahren für kurze sequenzvarianten | |
| DE69937447T2 (de) | Verfahren zur erkennung von nukleinsäuren | |
| EP1254254A2 (fr) | Molecules d'acide nucleique destinees a la detection de bacteries et d'unites phylogenetiques de bacteries | |
| DE69132830T2 (de) | Verfahren und Reagentien für die Identifikation von Bakterien | |
| DE69722028T2 (de) | Genetische marker und verfahren zur erkennung von listeria monocytogenes und listeriaspezien | |
| WO2003085129A1 (fr) | Detection de mycobacteries dans des materiaux cliniques | |
| DE10012540B4 (de) | Oligonukleotide und Verfahren zum spezifischen Nachweis von Mikroorganismen durch Polymerase-Kettenreaktion | |
| EP1606420B1 (fr) | Procede et kit pour detecter m. tuberculosis de maniere specifique | |
| KR101523877B1 (ko) | 실시간 중합효소연쇄반응법과 융해곡선분석을 이용하는 마이코박테리아의 동정 방법 | |
| DE102011118949B3 (de) | Kombiniertes Verfahren zum differentialdiagnostischen Nachweis von Bakterien des Mycobacterium-tuberculosis-Komplexes und von atypischen Pneumonie-Erregern | |
| KR101227204B1 (ko) | 이중 실시간 중합효소연쇄반응법을 이용한 결핵균과 항산성비결핵균의 검출 방법 | |
| KR20120113119A (ko) | 실시간 중합효소연쇄반응법과 융해곡선분석을 이용하는 마이코박테리아의 동정 방법 | |
| DE102005060090B4 (de) | Nachweis von coliformen Bakterien | |
| KR101515334B1 (ko) | 실시간 중합효소연쇄반응법과 융해곡선분석을 이용하는 마이코박테리아의 동정 방법 | |
| DE102005046361A1 (de) | Verfahren zur Unterscheidung von Salmonella-Serovaren | |
| KR101227302B1 (ko) | 이중 실시간 중합효소연쇄반응법을 이용한 결핵균과 항산성비결핵균의 검출 방법 | |
| Krysztopa-Grzybowska et al. | PCR-based genomic deletion analysis of RD-regions in the identification of mycobacteria isolated from adverse events following BCG vaccination or TB suspected cases | |
| JP2017201894A (ja) | 糖尿病の検査方法 | |
| DE102010010372B3 (de) | Identifizierung von Erregern des Mycobacterium tuberculosis Komplexes | |
| KR101227265B1 (ko) | 이중 실시간 중합효소연쇄반응법을 이용한 결핵균과 항산성비결핵균의 검출 방법 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| 17P | Request for examination filed |
Effective date: 20041108 |
|
| AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR |
|
| AX | Request for extension of the european patent |
Extension state: AL LT LV MK |
|
| 17Q | First examination report despatched |
Effective date: 20070306 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
| 18D | Application deemed to be withdrawn |
Effective date: 20070717 |